Dimerix (ASX:DXB) has spent the past month converting itself from a single-asset Phase 3 story into a two-drug renal company. On 17 July 2026 the Australian biopharmaceutical group acquired DMX-652, an oral once-daily USP30 inhibitor for acute kidney injury, from UK-based Mission Therapeutics. Six days later it confirmed a granted US composition-of-matter Patent running to 2043.

The stock price was in the spotlight after its share price recorded a significant jump. The most recent disclosure is a 6 August presentation by chief executive Dr Nina Webster setting out the company's Diversification strategy rather than fresh clinical data.

What happened?

The DMX-652 transaction gives Dimerix a mitochondrial-targeted candidate aimed at preventing acute kidney injury, particularly the kind following cardiac surgery, ischaemia, toxin exposure or sepsis. The package included composition-of-matter patents, an existing Investigational New Drug application with the US Food and Drug Administration, an approved Phase 2 protocol, and drug product sufficient for trials.

A completed Phase 1 study in 85 healthy volunteers reported no serious drug-related adverse events. On 23 July 2026 Dimerix confirmed the grant of a US patent covering the compound class, expiring in April 2043, meaning no new IND submission is required before recruitment can begin.

The story behind the numbers

Dimerix paid US$5 million upfront, with contingent consideration running to up to US$47 million on clinical development milestones, US$40 million on Marketing approval and up to US$175 million on sales-based milestones.

The March 2026 quarterly reported $26.6 million of cash at 31 March, on net operating outflow of $11.5 million. Across all five DMX-200 territory licensing deals, Dimerix has pointed to up to roughly $1.9 billion in aggregate upfronts and milestones, with more than $65 million already received.

Why this matters

For most ASX-listed biotechs the binary risk is brutal: one asset, one readout. Dimerix has partially defused that. Lead program DMX-200, a CCR2 antagonist for focal segmental glomerulosclerosis, is commercialised through partners in every major territory while the company retains development control. Adding a mechanistically unrelated second renal candidate spreads the risk further without an Equity raise.

What is driving the Investment case?

The core engine remains ACTION3, the Phase 3 trial for DMX-200, which has fully randomised 333 adult patients. An external blinded statistical review completed on 28 April 2026 confirmed the study retains greater than 90% power to detect a treatment effect on proteinuria as the primary endpoint.

The bull case

Dimerix has monetised DMX-200 across multiple regions before a single Phase 3 result, banking real cash and validation from partners. DMX-652 was cheap in upfront terms and starts from an FDA-cleared Phase 2 protocol rather than a blank page.

The bear case

Cash burn is the obvious pressure point, and additional non-dilutive funding was still under negotiation when last disclosed. The last adult patient in ACTION3 is expected to take their final dose in March 2028, so the definitive efficacy answer sits years away while costs run now. DMX-652 has been tested only in healthy volunteers, never in patients with kidney injury.

What could move the share price next?

Identifiable near-term items include the start of the DMX-652 Phase 2 study, completion of negotiations over additional non-dilutive funding, and milestone payments falling due under existing licensing agreements.

Outlook

Dimerix now looks less like a one-drug lottery ticket and more like a small renal specialist with two shots and a partner-funded Revenue tail. The trade-off is time and treasury: the value-defining ACTION3 data is not near, and the company must fund a multi-year gap without diluting holders.